Tumor Biology

, Volume 36, Issue 12, pp 9405–9410 | Cite as

High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer

  • Feng Wei
  • Fan Yang
  • Xiangli Jiang
  • Wenwen Yu
  • Xiubao Ren
Research Article


The involvement of alarmin high-mobility group nucleosome-binding protein 1 (HMGN1) in non-small cell lung cancer (NSCLC) is unknown. To address the presence of HMGN1 in the serum of different stages of NSCLC patients and healthy controls, we enrolled a consecutive sample of adult serum at diagnosis and correlated it with clinicopathologic outcomes. A total of 100 NSCLC patients and 23 healthy volunteers were enrolled from January 2012 through December 2013. Serum HMGN1 levels were determined by enzyme-linked immunosorbent assay (ELISA). Additionally, HMGN1 levels in 50 NSCLC patients with early-stage disease who received curative pneumonectomy were correlated with survivals. Kaplan-Meier plots were used to analyze the data. The patients with NSCLC were characterized by significantly higher serum levels of HMGN1 (0.4585 ± 0.0640 ng/ml) compared to those in healthy controls (0.3578 ± 0.0304 ng/ml). The serum HMGN1 levels were 0.4027 ± 0.0271 ng/ml, 0.4604 ± 0.0328 ng/ml, 0.5408 ± 0.0459 ng/ml, and 0.4213 ± 0.0341 ng/ml in patients with TNM stages I, II, IV, and IV, respectively (p < 0.001). There were significant differences among four groups (p < 0.001). Additionally, a positive correlation between serum HMGN1 and tumor stage was found in local disease, while serum HMGN1 level in metastatic NSCLC patients was significantly decreased. The Kaplan-Meier plots showed that patients with high serum HMGN1 had a poorer overall survival (OS) after curative pneumonectomy than those with low serum HMGN1 (p = 0.019). Inflammation triggered by alarmins plays a role in NSCLC pathogenesis. HMGN1 can serve as a useful clinical parameter for evaluating disease progression and predicting the outcomes for early-stage patients with NSCLC undergoing pneumonectomy.





This work has been funded, in part, by grants from the National Natural Science Foundation of China (No. 30901376) and Tianjin Application Foundation and Advanced Technology Research Program (No. 13JCYBJC41400, No. 14JCTPJC00476).

Conflicts of interest


Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Bianchi ME, Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev. 2005;15(5):496–506.CrossRefPubMedGoogle Scholar
  3. 3.
    Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol. 1999;19(8):5237–46.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Birger Y et al. Increased tumorigenicity and sensitivity to ionizing radiation upon loss of chromosomal protein HMGN1. Cancer Res. 2005;65(15):6711–8.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Birger Y et al. Chromosomal protein HMGN1 enhances the rate of DNA repair in chromatin. EMBO J. 2003;22(7):1665–75.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Yang D et al. High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses. J Exp Med. 2012;209(1):157–71.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wei F et al. The Alarmin HMGN1 contributes to antitumor immunity and is a potent immunoadjuvant. Cancer Res. 2014;74(21):5989–98.CrossRefPubMedGoogle Scholar
  8. 8.
    Mange A et al. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer. Clin Cancer Res. 2012;18(7):1992–2000.CrossRefPubMedGoogle Scholar
  9. 9.
    Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014;3(4):242–9.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Coffelt SB, Scandurro AB. Tumors sound the alarmin(s). Cancer Res. 2008;68(16):6482–5.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ellerman JE et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007;13(10):2836–48.CrossRefPubMedGoogle Scholar
  12. 12.
    Sims GP et al. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367–88.CrossRefPubMedGoogle Scholar
  13. 13.
    Tang D et al. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010;1799(1-2):131–40.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Li Y et al. Serum high mobility group box protein 1 as aclinical marker for ovarian cancer. Neoplasma. 2014;61(5):579–84.CrossRefPubMedGoogle Scholar
  15. 15.
    Shang GH et al. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med. 2009;103(12):1949–53.CrossRefPubMedGoogle Scholar
  16. 16.
    Wang JL et al. Expression of high mobility group box - B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC). Asian Pac J Cancer Prev. 2014;15(12):4865–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang C et al. MiRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in non-small cell lung cancer. Acta Biochim Biophys Sin. 2013;45(12):1055–61.CrossRefPubMedGoogle Scholar
  18. 18.
    Zhang X, Wang H, Wang J. Expression of HMGB1 and NF-kappaB p65 and its significance in non-small cell lung cancer. Contemp Oncol. 2013;17(4):350–5.Google Scholar
  19. 19.
    Kang R et al. HMGB1 in health and disease. Mol Asp Med. 2014;40C:1–116.Google Scholar
  20. 20.
    Yang D et al. The alarmin functions of high-mobility group proteins. Biochim Biophys Acta. 2010;1799(1-2):157–63.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Feng Wei
    • 1
  • Fan Yang
    • 1
    • 2
  • Xiangli Jiang
    • 1
  • Wenwen Yu
    • 1
  • Xiubao Ren
    • 1
    • 2
  1. 1.Department of ImmunologyTianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin; Key Laboratory of Cancer Prevention and Therapy, TianjinHexi DistrictPeople’s Republic of China
  2. 2.Department of BiotherapyTianjin Medical University Cancer Institute and HospitalHexi DistrictPeople’s Republic of China

Personalised recommendations